1-3 of 3
Shannon Cope
Close
Sort by
Journal Articles

Matching-Adjusted Indirect Comparisons of Efficacy Outcomes in Patients with Relapsed and Refractory Multiple Myeloma for Idecabtagene Vicleucel (KarMMa) Versus Selinexor Plus Dexamethasone (STORM Part 2) and Belantamab Mafodontin (DREAMM-2): Updated Analysis with Longer Follow-up

Paula Rodríguez-Otero, Ali Mojebi, Dieter Ayers, Devender Dhanda, James Farrell, Faith E. Davies, Michel Delforge, Katja Weisel, Kevin Towle, Tom Marshall, Clyde Caisip, Shannon Cope
Journal: Blood
Blood (2021) 138 (Supplement 1): 1978.
https://doi.org/10.1182/blood-2021-145321
Published: 2021
Journal Articles

A Matching-Adjusted Indirect Comparison of Efficacy Outcomes for Idecabtagene Vicleucel (ide-cel, bb2121), a Bcma-Directed CAR T Cell Therapy Versus Conventional Care in Triple-Class-Exposed Relapsed and Refractory Multiple Myeloma

Nina Shah, MD, Dieter Ayers, Faith E. Davies, Shannon Cope, Ali Mojebi, Kejal Parikh, Devender Dhanda, Parameswaran Hari, MD MRCP, Payal Patel, Liping Huang, PhD, Kristen Hege, Sujith Dhanasiri
Journal: Blood
Blood (2020) 136 (Supplement 1): 6–7.
https://doi.org/10.1182/blood-2020-136730
Published: 2020
Journal Articles

Expert Elicitation of Long-Term Survival for Pediatric Acute Lymphoblastic Leukemia Patients Receiving CTL019 in Eliana Phase II Study

Shannon Cope, MSc, Dieter Ayers, MSc, Tiffany Shih, PhD, Jie Zhang, PhD, Jeroen Jansen, PhD, Katherine Batt, MD MSc
Journal: Blood
Blood (2017) 130 (Supplement 1): 3377.
https://doi.org/10.1182/blood.V130.Suppl_1.3377.3377
Published: 2017